Jiangsu Recbio Technology Co., Ltd. (HKG:2179)

Market Cap	2.41B -22.5%
Revenue (ttm)	568.00K -76.7%
Net Income	-555.95M
EPS	-0.93
Shares Out	616.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	4.000
Day's Range	n/a
52-Week Range	1.000 - 6.700
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 466
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2179

Financial Performance

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 11, 2026

Data Sources Report a data error